CARMILA 14.740 € (-0,41 %) LVMH 398.800 € (+0,49 %) 
AIRBUS 193.100 € (+0,36 %) 
SHELL PLC 42.725 € (+1,58 %) SANOFI 72.000 € (+0,29 %) 
TotalEnergiesGabon 223.000 € (-1,55 %) AKZO NOBEL 56.460 € (-0,67 %) ING GROEP N.V. 31.880 € (+0,27 %) FORVIA 8.826 € (+1,26 %) TOTALENERGIES 80.000 € (+0,01 %) AIR LIQUIDE 168.220 € (+0,43 %) LISI 61.900 € (0,00 %) CEGEDIM 11.320 € (-1,39 %) INTERPARFUMS 30.300 € (-0,26 %) GECINA 63.250 € (-0,78 %) COVIVIO 45.980 € (-0,86 %) SAFRAN 333.000 € (-0,98 %) ASML HOLDING 1 537.000 € (+0,95 %) D.A.T.E 21.850 € (+1,63 %) VETOQUINOL 74.600 € (-1,19 %) HERMES INTL 1 381.500 € (+2,52 %) ACCOR 45.900 € (+0,02 %) 
AEGON 7.808 € (-0,54 %) HAFFNER ENERGY 0.864 € (+12,21 %) TRIODOS BANK 38.000 € (-1,17 %) EUTELSAT COMMUNIC. 1.653 € (-3,19 %) ARVERNE GROUP 6.200 € (-5,49 %) TOMTOM 3.756 € (-1,93 %) 
THEON INTERNAT 29.240 € (-3,50 %) SOLUTIONS 30 SE 0.465 € (-4,22 %) JACQUET METALS 20.200 € (-2,42 %) BUREAU VERITAS 26.570 € (-1,19 %) AXA 43.980 € (-0,05 %) HEXAOM 21.500 € (0,00 %) ABN AMRO BANK N.V. 43.740 € (+0,21 %) ESSILORLUXOTTICA 146.100 € (+1,53 %) AIR FRANCE -KLM 11.650 € (-0,47 %) ARCURE 2.170 € (-9,58 %) PLANISWARE 24.050 € (-0,62 %) ADP 110.500 € (-0,27 %) TRIGANO 130.900 € (-0,23 %) PROSUS 36.015 € (-0,21 %) INVENTIVA 2.955 € (+3,87 %) REXEL 35.100 € (-3,33 %) ABIVAX 83.850 € (+2,38 %) THALES 226.000 € (-1,48 %) CAPGEMINI 102.950 € (-1,48 %) TIKEHAU CAPITAL 16.240 € (-0,37 %) MAGNUM 16.488 € (-0,31 %) HEIJMANS KON 90.500 € (+5,36 %) NN GROUP 79.520 € (-0,55 %) CALIBRE 0.000 € (+50,00 %) TKH GROUP 53.150 € (-1,02 %) JCDECAUX 25.000 € (+0,16 %) SPARTOO 0.270 € (+3,85 %) DBV TECHNOLOGIES 2.072 € (+2,47 %) KALRAY 4.365 € (-12,70 %) SMCP 6.065 € (+0,08 %) GTT 219.000 € (+0,09 %) THERACLION 0.717 € (-4,40 %) |
28/09/2026 17:53
EQS-Adhoc: MeVis Medical Solutions AG: Forecast Adjustment for Fiscal Year 2025/2026EQS-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Forecast / Full year Bremen, September 28, 2026 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software company in the field of image-based medicine, is revising its forecast for the current fiscal year based on preliminary results. According to the management’s current assessment, the company will not meet its financial targets. The reasons for this continue to be lower revenue due to subdued demand in the mammography sector for the customer Hologic and the persistently slow rollout of lung cancer screening in Germany. Based on preliminary figures, management now expects revenue for the 2025/2026 fiscal year to decline year-over-year to a range of €15.0 million to €15.5 million (previous forecast: €16.5 million to €17.0 million). Consequently, the company expects negative earnings before interest and taxes (EBIT) for the 2025/2026 fiscal year in the range of € -1.0 million to € -1.5 million (previous forecast: € 0.5 million to € 1.0 million), assuming a stable exchange rate of 1.16 USD/EUR. ************************************************************************ Contact: Kirchhoff, Marcus / CEOEnd of Inside Information 28-Sep-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
2406544 28-Sep-2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière